UroGen Pharma (URGN) Treasury Shares (2016 - 2025)
UroGen Pharma's (URGN) quarterly Treasury Shares came in at $1.9 million in Q4 2025, up 27.83% YoY from $1.5 million in Q4 2024, and up 27.83% on a QoQ basis from $1.5 million in Q4 2024.
UroGen Pharma (URGN) Treasury Shares (2016 - 2025) Analysis & Trends
UroGen Pharma (URGN) has 10 years of Treasury Shares data on file, last reported at $1.9 million in Q4 2025.
- Quarterly Treasury Shares rose 27.83% year-over-year to $1.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.9 million (up 27.83% YoY) and the FY2025 annual result came in at $1.9 million, up 27.83% from the prior year.
- Treasury Shares rose to $1.9 million in Q4 2025, from $1.5 million in the prior quarter.
- In the past five years, Treasury Shares ranged from a high of $1.9 million in Q4 2025 to a low of $690955.0 in Q4 2022.
- A 5-year average of $1.2 million and a median of $1.1 million in 2023 frame the typical range for Treasury Shares.
- Annual changes were most pronounced in 2022 — Treasury Shares decreased 8.27% — and 2023, when it surged 59.01%.
- Tracing URGN's Treasury Shares over 5 years: stood at $753274.0 in 2021, then declined by 8.27% to $690955.0 in 2022, then jumped by 59.01% to $1.1 million in 2023, then surged by 37.24% to $1.5 million in 2024, then increased by 27.83% to $1.9 million in 2025.
- The last three Treasury Shares figures came in at $1.9 million (Q4 2025), $1.5 million (Q4 2024), and $1.1 million (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 36.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 5.08 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.72 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 92,219.00 |
| 10 | UroGen Pharma | 2.36 Bn | 2.25 Bn | 65.88 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.93 Mn |
| Dec 31, 2025 | 1.93 Mn |
| Dec 31, 2024 | 1.51 Mn |
| Dec 31, 2024 | 1.51 Mn |
| Dec 31, 2023 | 1.10 Mn |
| Dec 31, 2023 | 1.10 Mn |
| Dec 31, 2022 | 690,955.00 |
| Dec 31, 2022 | 690,955.00 |
| Dec 31, 2021 | 753,274.00 |
| Dec 31, 2021 | 753,274.00 |
| Dec 31, 2020 | 720,416.00 |
| Dec 31, 2020 | 720,416.00 |
| Dec 31, 2019 | 519,427.00 |
| Dec 31, 2019 | 519,427.00 |
| Dec 31, 2018 | 263,699.00 |
| Dec 31, 2018 | 263,699.00 |
| Dec 31, 2017 | 276,560.00 |
| Dec 31, 2017 | 276,560.00 |
| Dec 31, 2016 | 275,200.00 |
| Dec 31, 2016 | 275,200.00 |